Alaunos Therapeutics, Inc. Preferred Stock Dividends, Income Statement Impact
Alaunos Therapeutics, Inc. (TCRT) reported Preferred Stock Dividends, Income Statement Impact of $342.00 thousand for the 3-month period ending 2018-12-31, per its 10-K filed 2020-03-02.
Discontinued › Expense Statement › Operating Expenses
us-gaap:PreferredStockDividendsIncomeStatementImpact · last filed 2021-03-01
- Alaunos Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-12-31 was $342.00K, a 93.16% decline year-over-year.
- Alaunos Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-09-30 was $6.07M, a 23.88% increase year-over-year.
- Alaunos Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-06-30 was $5.46M, a 12.27% increase year-over-year.
- Alaunos Therapeutics, Inc. preferred stock dividends, income statement impact for the quarter ending 2018-03-31 was $5.12M, a 22.75% increase year-over-year.
- Alaunos Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2018 was $17.00M, a 10.24% decline from fiscal 2017.
- Alaunos Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2017 was $18.94M, a 165.87% increase from fiscal 2016.
- Alaunos Therapeutics, Inc. preferred stock dividends, income statement impact for fiscal 2016 was $7.12M.
| Period end | Preferred Stock Dividends, Income Statement Impact 3 month | Preferred Stock Dividends, Income Statement Impact 6 month | Preferred Stock Dividends, Income Statement Impact 9 month | Preferred Stock Dividends, Income Statement Impact 12 month |
|---|---|---|---|---|
| 2018-12-31 | $342.00K 10-K · filed 2020-03-02 | $6.42M derived: sum of 2 quarters · filed 2020-03-02 | $11.88M derived: sum of 3 quarters · filed 2020-03-02 | $17.00M 10-K · filed 2021-03-01 |
| 2018-09-30 | $6.07M 10-K · filed 2020-03-02 | $11.54M derived: sum of 2 quarters · filed 2020-03-02 | $16.66M 10-Q · filed 2019-11-07 | $21.66M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-06-30 | $5.46M 10-K · filed 2020-03-02 | $10.58M 10-Q · filed 2019-08-08 | $15.58M derived: sum of 3 quarters · filed 2020-03-02 | $20.48M derived: sum of 4 quarters · filed 2020-03-02 |
| 2018-03-31 | $5.12M 10-K · filed 2020-03-02 | $10.12M derived: sum of 2 quarters · filed 2020-03-02 | $15.02M derived: sum of 3 quarters · filed 2020-03-02 | $19.89M derived: sum of 4 quarters · filed 2020-03-02 |
| 2017-12-31 | $5.00M 10-K · filed 2019-03-05 | $9.90M derived: sum of 2 quarters · filed 2019-03-05 | $14.77M derived: sum of 3 quarters · filed 2019-03-05 | $18.94M 10-K · filed 2020-03-02 |
| 2017-09-30 | $4.90M 10-K · filed 2019-03-05 | $9.77M derived: sum of 2 quarters · filed 2019-03-05 | $13.94M 10-Q · filed 2018-11-09 | $17.47M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-06-30 | $4.87M 10-K · filed 2019-03-05 | $9.04M 10-Q · filed 2018-08-08 | $12.57M derived: sum of 3 quarters · filed 2019-03-05 | $16.16M derived: sum of 4 quarters · filed 2019-03-05 |
| 2017-03-31 | $4.17M 10-K · filed 2019-03-05 | $7.70M derived: sum of 2 quarters · filed 2019-03-05 | $11.29M derived: sum of 3 quarters · filed 2019-03-05 | |
| 2016-12-31 | $3.53M 10-K · filed 2018-03-01 | $7.12M derived: sum of 2 quarters · filed 2018-03-01 | $7.12M 10-K · filed 2019-03-05 | |
| 2016-09-30 | $3.59M 10-Q · filed 2017-11-06 | $3.59M 10-Q · filed 2017-11-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Genprex, Inc. (GNPX) | United States | $0.003B | -0.02 |
| Silo Pharma, Inc. (SILO) | United States | $0.003B | -1.57 |
| GeoVax Labs, Inc. (GOVX) | United States | $0.003B | -0.45 |
| Petros Pharmaceuticals, Inc. (PTPI) | United States | $0.003B | |
| Sunshine Biopharma Inc. (SBFM) | $0.003B | ||
| Matinas BioPharma Holdings, Inc. (MTNB) | United States | $0.003B | |
| ZyVersa Therapeutics, Inc. (ZVSA) | United States | $0.002B | |
| Aptevo Therapeutics Inc. (APVO) | United States | $0.003B | |
| BioXcel Therapeutics, Inc. (BTAI) | United States | $0.002B | |
| JUPITER NEUROSCIENCES, INC. (JUNS) | United States | $0.002B | -0.02 |